


Supplementary figure 1: Treatment pathways in patients with mCRC enrolled in the UK Named Patient Programme who did not receive trifluridine/tipiracil

First line (inner circle) and second line (outer circle) treatments in patients who received ≥ 1 dose of trifluridine/tipiracil; B) First line (inner circle) and second line (outer circle) treatments in patients who did not receive trifluridine/tipiracil.



How to interpret: The inner pie chart shows the distribution of first line treatments for mCRC; the outer circle shows the second line treatments that patients in the corresponding segment of the inner circle subsequently received. E.g. chart A shows that 7% of patients received FOLFIRI (first line) followed by trifluridine/tipiracil (second line). Percentages are not presented for groups with <5% of patients. Treatments were grouped based on primary treatment. Treatment regimens were grouped as follows: (i) 'FOLFIRI based' includes FOLFIRI only or in combination with one or more of the following: aflibercept, bevacizumab, capecitabine, cetuximab, panitumumab. (ii) 'FOLFOX based' includes FOLFOX only or in combination with one or more of the following: bevacizumab, capecitabine, cetuximab, irinotecan, other. (iii) 'CAPOX based' includes CAPOX only or CAPOX with bevacizumab and/or other. (iv) 'CAPIRI based' includes CAPIRI only or CAPIRI with bevacizumab or cetuximab. (v) 'Other capecitabine based' includes capecitabine only or in combination with one or more of the following: aflibercept, bevacizumab, mitomycin, other. (vi) 'Other 5-FU based' includes 5-Fluorouracil (5-FU) only or 5-FU plus capecitabine or other. (vii) 'Other oxaliplatin based' includes oxaliplatin only, oxaliplatin with irinotecan and cetuximab and oxaliplatin with other. (viii) 'Other irinotecan based' includes irinotecan only or in combination with one or more of the following: aflibercept, bevacizumab, cetuximab, other. (ix) 'Cetuximab based' includes cetuximab only or in combination with panitumumab. (x) 'Regorafenib based' includes regorafenib only or with other.

Supplementary table 1: First line regimen in patients enrolled in the United Kingdom Named Patient Programme

First-line regimens for metastatic disease	Patients receiving ≥ 1 dose of trifluridine/tipiracil	Patients not commencing trifluridine/tipiracil
FOLFIRI	35 (18%)	9 (16%)
FOLFOX	33 (17%)	15 (27%)
CAPOX	29 (15%)	7 (13%)
FOLFOX+BEV	24 (12%)	≤ 5 ($\leq 9\%$)
FOLFIRI+CET	16 (8%)	≤ 5 ($\leq 9\%$)
FOLFIRI+BEV	14 (7%)	≤ 5 ($\leq 9\%$)
CAPOX+BEV	10 (5%)	≤ 5 ($\leq 9\%$)
FOLFOX+CET	7 (4%)	≤ 5 ($\leq 9\%$)
CAPIRI	≤ 5 ($\leq 3\%$)	≤ 5 ($\leq 9\%$)
Capecitabine	≤ 5 ($\leq 3\%$)	≤ 5 ($\leq 9\%$)
CAPIRI+BEV	≤ 5 ($\leq 3\%$)	0
FOLFOXIRI+BEV	≤ 5 ($\leq 3\%$)	0
FOLFOX+other	≤ 5 ($\leq 3\%$)	0
CAPIRI+CET	≤ 5 ($\leq 3\%$)	≤ 5 ($\leq 9\%$)
5-FU+BEV	≤ 5 ($\leq 3\%$)	0
CAPOX+BEV+other	≤ 5 ($\leq 3\%$)	0
CAPOX-other	≤ 5 ($\leq 3\%$)	≤ 5 ($\leq 9\%$)
FOLFIRI+AFL	≤ 5 ($\leq 3\%$)	0
FOLFIRI+other	≤ 5 ($\leq 3\%$)	≤ 5 ($\leq 9\%$)
FOLFOX+BEV+CET	≤ 5 ($\leq 3\%$)	0
FOLFOXIRI	0	≤ 5 ($\leq 9\%$)
Oxaliplatin	≤ 5 ($\leq 3\%$)	0
OXIRI+CET	≤ 5 ($\leq 3\%$)	0
FOLFOX+CAP+CET	0	≤ 5 ($\leq 9\%$)
Irinotecan	0	≤ 5 ($\leq 9\%$)
OX+other	0	≤ 5 ($\leq 9\%$)

Groups containing < 5 patients have been censored to preserve patient confidentiality.